Cadrenal Therapeutics
CVKD | NASDAQ
$1.40
-$0.11 (-7.28%)
At close: Nov 16, 2026, 4:00 PM ET
$1.57
+$0.17 (+12.39%)
After-hours:
Nov 16, 2026, 7:42 PM ET
-7.28%
(1D)No price chart data available for 1D timeframe.
Rating
31.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #749/1021 (Top 73%)
Key Statistics
Market Data
Market Cap $4.99M
1D Range
1.39 1.54
52W Range
0.87 12.29
Valuation (TTM)
PE -0.29
PB 1.22
EV/EBITDA -0.23
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $32.00
Cash Flow
FCF Yield -203.5%
SBC Adj. FCF Yield -238.0%
SBC Impact -17.0%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 10.4% |
N/A
FCF 3Y | 5Y -30.9% |
N/A
Returns
ROA -206.6%
ROE -406.4%
ROIC -284.8%
Financial Health
Net Cash
$2.39M
Current Ratio 3.73
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent t...
Sector Healthcare
Industry Biotechnology
Employees 5
IPO Date Jan 20, 2023
Website www.cadrenal.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$32.00
Upside
+2185.71%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CVKD